Paul Capital injects £17.5m into ML Laboratories

US private equity firm Paul Capital is funding US clinical trials of Adept, a product manufactured by UK-based pharmaceutical business ML Laboratories

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this